[1]姜运秋,田颖.长期抗凝者植入心脏植入装置围手术期抗凝策略[J].心血管病学进展,2016,(1):8-11.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.003]
　JIANG Yunqiu,TIAN Ying.Perioperative Anticoagulation of Cardiovascular Implantable Electronic Devices Implantation in Patients Receiving Long-term Anticoagulant Therapy[J].Advances in Cardiovascular Diseases,2016,(1):8-11.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.003]

点击复制

长期抗凝者植入心脏植入装置围手术期抗凝策略()

分享到：

参考文献/References:

[1] Connolly SJ, Kerr CR, Gent M, et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes[J]. N Engl J Med, 2000,342(19):1385-1391.
[2] Nascimento T, Birnie DH, Healey JS, et al. Managing novel oral anticoagulants in patients with atrial fibrillation undergoing device surgery: Canadian survey[J]. Can J Cardiol, 2014,30(2):231-236.
[3] Robinson M, Healey JS, Eikelboom J, et al. Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators[J]. Pacing Clin Electrophysiol,2009,32(3):378-382.
[4] Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy:antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest,2012,141(2):e326-e350.
[5] Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2014,63(22):e57-e185.
[6] Camm AJ, Lip GY, de Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association[J]. Eur Heart J, 2012,33(21):2719-2747.
[7] Tompkins C, Cheng A, Dalal D, et al. Dual antiplatelet therapy and heparin “bridging” significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation[J]. J Am Coll Cardiol,2010,55(21):2376-2382.
[8] Steinberg BA, Peterson ED, Kim S, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation(ORBIT-AF)[J]. Circulation,2015,131(5):488-494.
[9] Cano O, Osca J, Sancho-Tello MJ, et al. Morbidity associated with three different antiplatelet regimens in patients undergoing implantation of cardiac rhythm management devices[J]. Europace,2011,13(3):395-401.
[10] Han ZH, Ren XJ, Wang Y. Anticoagulation management of patients with long-term warfarin therapy after valve replacement during the perioperative period of pacemaker implantation[J]. Int J Clin Exp Med,2013,6(7):594-598.
[11] Tafur AJ, McBane R, Wysokinski WE, et al. Predictors of major bleeding in peri-procedural anticoagulation management[J]. J Thromb Haemost,2012,10(2):261-267.
[12] Wiegand UK, LeJeune D, Boguschewski F, et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery[J]. Chest,2004,126(4):1177-1186.
[13] Schulman S, Healey JS, Douketis JD, et al. Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: a randomized trial[J]. Thromb Res,2014,134(4):814-818.
[14] Dai Y, Chen KP, Hua W, et al. Dual antiplatelet therapy increases pocket hematoma complications in Chinese patients with pacemaker implantation[J]. J Geriatr Cardiol,2015,12(4):383-387.
[15] Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation[J]. N Engl J Med,2015,373(9):823-833.
[16] Birnie DH, Healey JS, Wells GA, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation[J]. N Engl J Med,2013,368(22):2084-2093.
[17] Al-Khadra AS. Implantation of pacemakers and implantable cardioverter defibrillators in orally anticoagulated patients[J]. Pacing Clin Electrophysiol,2003,26(1):511-514.
[18] Giudici MC, Paul DL, Bontu P, et al. Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy[J]. Pacing Clin Electrophysiol, 2004,27(3):358-360.
[19] Cano Ó, Andrés A, Jiménez R, et al. Systematic implantation of pacemaker/ICDs under active oral anticoagulation irrespective of patient's individual preoperative thromboembolic risk[J]. Pacing Clin Electrophysiol,2015,38(6):723-730.
[20] Thal S, Moukabary T, Boyella R, et al. The relationship between warfarin, aspirin, and clopidogrel continuation in the peri-procedural period and the incidence of hematoma formation after device implantation[J]. Pacing Clin Electrophysiol,2010,33(4):385-388.
[21] Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy(RE-LY)randomized trial[J]. Circulation,2012,126(3):343-348.
[22] Rowley CP, Bernard ML, Brabham WW, et al. Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices[J]. Am J Cardiol, 2013,111(8):1165-1168.